Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Regeneron Pharmaceuticals Inc., solvency ratios (quarterly data)
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Regeneron Pharmaceuticals Inc. debt to equity ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Regeneron Pharmaceuticals Inc. debt to capital ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Regeneron Pharmaceuticals Inc. debt to assets ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Regeneron Pharmaceuticals Inc. financial leverage ratio decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 exceeding Q2 2024 level. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Regeneron Pharmaceuticals Inc. interest coverage ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
Debt to Equity
Regeneron Pharmaceuticals Inc., debt to equity calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 1,500,000) | —) | ||||||
| Finance lease liabilities, current portion | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 719,700) | 719,000) | 718,400) | 717,800) | —) | —) | —) | —) | ||||||
| Long-term debt | 1,984,400) | 1,984,000) | 1,983,600) | 1,983,300) | 1,982,900) | 1,982,600) | 1,982,200) | 1,981,800) | 1,981,400) | 1,981,100) | 1,980,700) | 1,980,400) | 1,980,000) | 1,979,600) | 1,979,200) | 1,978,900) | 1,978,500) | 1,978,300) | —) | —) | ||||||
| Finance lease liabilities, excluding current portion | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | —) | —) | —) | —) | 717,200) | 716,500) | 715,900) | 715,200) | ||||||
| Total debt | 2,704,400) | 2,704,000) | 2,703,600) | 2,703,300) | 2,702,900) | 2,702,600) | 2,702,200) | 2,701,800) | 2,701,400) | 2,701,100) | 2,700,700) | 2,700,400) | 2,699,700) | 2,698,600) | 2,697,600) | 2,696,700) | 2,695,700) | 2,694,800) | 2,215,900) | 715,200) | ||||||
| Stockholders’ equity | 29,353,600) | 29,325,900) | 28,205,800) | 26,991,100) | 25,973,100) | 24,904,400) | 24,017,900) | 23,495,200) | 22,664,000) | 21,438,800) | 20,687,800) | 19,914,700) | 18,768,800) | 17,258,000) | 15,127,300) | 11,977,000) | 11,025,300) | 10,125,500) | 9,057,400) | 12,133,000) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to equity1 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 | 0.14 | 0.14 | 0.16 | 0.18 | 0.23 | 0.24 | 0.27 | 0.24 | 0.06 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 20.19 | 11.78 | 10.42 | 9.24 | 5.73 | 5.02 | 4.74 | 4.68 | 3.67 | 4.35 | 4.98 | 4.51 | 4.98 | 5.96 | 6.53 | 6.24 | 6.58 | 5.70 | 5.94 | — | ||||||
| Amgen Inc. | 10.23 | 8.02 | 10.57 | 12.75 | 10.37 | 7.90 | 9.08 | 11.52 | 10.64 | 10.60 | 15.10 | 40.23 | 4.97 | 4.57 | 3.98 | 3.50 | 3.51 | 3.13 | 3.21 | 3.36 | ||||||
| Bristol-Myers Squibb Co. | 3.04 | 2.90 | 3.08 | 3.38 | 1.35 | 1.30 | 1.18 | 1.19 | 1.27 | 1.20 | 1.29 | 1.42 | 1.24 | 1.20 | 1.23 | 1.23 | 1.34 | 0.90 | 0.95 | 0.94 | ||||||
| Danaher Corp. | 0.32 | 0.34 | 0.34 | 0.34 | 0.34 | 0.42 | 0.38 | 0.39 | 0.39 | 0.41 | 0.43 | 0.47 | 0.49 | 0.54 | 0.48 | 0.50 | 0.53 | 0.57 | 0.62 | 0.84 | ||||||
| Eli Lilly & Co. | 2.37 | 2.19 | 2.13 | 2.05 | 2.34 | 1.80 | 1.70 | 1.69 | 1.52 | 1.58 | 1.97 | 1.77 | 1.88 | 2.20 | 2.56 | 2.35 | 2.94 | 3.51 | 3.99 | 5.60 | ||||||
| Gilead Sciences Inc. | 1.38 | 1.26 | 1.28 | 1.44 | 1.09 | 1.12 | 1.19 | 1.20 | 1.19 | 1.20 | 1.30 | 1.32 | 1.27 | 1.29 | 1.53 | 1.59 | 1.73 | 1.68 | 1.34 | 1.09 | ||||||
| Johnson & Johnson | 0.51 | 0.51 | 0.58 | 0.48 | 0.43 | 0.42 | 0.61 | 0.75 | 0.52 | 0.43 | 0.43 | 0.44 | 0.46 | 0.48 | 0.48 | 0.51 | 0.56 | 0.59 | 0.48 | 0.45 | ||||||
| Merck & Co. Inc. | 0.80 | 0.86 | 0.87 | 0.85 | 0.93 | 0.85 | 0.95 | 0.66 | 0.67 | 0.68 | 0.73 | 0.78 | 0.87 | 0.74 | 0.80 | 1.16 | 1.26 | 0.98 | 1.12 | 1.07 | ||||||
| Pfizer Inc. | 0.73 | 0.73 | 0.79 | 0.75 | 0.81 | 0.66 | 0.66 | 0.36 | 0.37 | 0.40 | 0.46 | 0.44 | 0.50 | 0.53 | 0.56 | 0.58 | 0.63 | 0.97 | 0.99 | 0.80 | ||||||
| Thermo Fisher Scientific Inc. | 0.63 | 0.72 | 0.75 | 0.78 | 0.75 | 0.78 | 0.78 | 0.83 | 0.78 | 0.67 | 0.72 | 0.81 | 0.85 | 0.56 | 0.51 | 0.53 | 0.63 | 0.66 | 0.71 | 0.70 | ||||||
| Vertex Pharmaceuticals Inc. | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= 2,704,400 ÷ 29,353,600 = 0.09
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Regeneron Pharmaceuticals Inc. debt to equity ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
Debt to Capital
Regeneron Pharmaceuticals Inc., debt to capital calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 1,500,000) | —) | ||||||
| Finance lease liabilities, current portion | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 719,700) | 719,000) | 718,400) | 717,800) | —) | —) | —) | —) | ||||||
| Long-term debt | 1,984,400) | 1,984,000) | 1,983,600) | 1,983,300) | 1,982,900) | 1,982,600) | 1,982,200) | 1,981,800) | 1,981,400) | 1,981,100) | 1,980,700) | 1,980,400) | 1,980,000) | 1,979,600) | 1,979,200) | 1,978,900) | 1,978,500) | 1,978,300) | —) | —) | ||||||
| Finance lease liabilities, excluding current portion | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | —) | —) | —) | —) | 717,200) | 716,500) | 715,900) | 715,200) | ||||||
| Total debt | 2,704,400) | 2,704,000) | 2,703,600) | 2,703,300) | 2,702,900) | 2,702,600) | 2,702,200) | 2,701,800) | 2,701,400) | 2,701,100) | 2,700,700) | 2,700,400) | 2,699,700) | 2,698,600) | 2,697,600) | 2,696,700) | 2,695,700) | 2,694,800) | 2,215,900) | 715,200) | ||||||
| Stockholders’ equity | 29,353,600) | 29,325,900) | 28,205,800) | 26,991,100) | 25,973,100) | 24,904,400) | 24,017,900) | 23,495,200) | 22,664,000) | 21,438,800) | 20,687,800) | 19,914,700) | 18,768,800) | 17,258,000) | 15,127,300) | 11,977,000) | 11,025,300) | 10,125,500) | 9,057,400) | 12,133,000) | ||||||
| Total capital | 32,058,000) | 32,029,900) | 30,909,400) | 29,694,400) | 28,676,000) | 27,607,000) | 26,720,100) | 26,197,000) | 25,365,400) | 24,139,900) | 23,388,500) | 22,615,100) | 21,468,500) | 19,956,600) | 17,824,900) | 14,673,700) | 13,721,000) | 12,820,300) | 11,273,300) | 12,848,200) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to capital1 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.12 | 0.12 | 0.13 | 0.14 | 0.15 | 0.18 | 0.20 | 0.21 | 0.20 | 0.06 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 0.95 | 0.92 | 0.91 | 0.90 | 0.85 | 0.83 | 0.83 | 0.82 | 0.79 | 0.81 | 0.83 | 0.82 | 0.83 | 0.86 | 0.87 | 0.86 | 0.87 | 0.85 | 0.86 | 1.12 | ||||||
| Amgen Inc. | 0.91 | 0.89 | 0.91 | 0.93 | 0.91 | 0.89 | 0.90 | 0.92 | 0.91 | 0.91 | 0.94 | 0.98 | 0.83 | 0.82 | 0.80 | 0.78 | 0.78 | 0.76 | 0.76 | 0.77 | ||||||
| Bristol-Myers Squibb Co. | 0.75 | 0.74 | 0.75 | 0.77 | 0.57 | 0.56 | 0.54 | 0.54 | 0.56 | 0.54 | 0.56 | 0.59 | 0.55 | 0.55 | 0.55 | 0.55 | 0.57 | 0.47 | 0.49 | 0.48 | ||||||
| Danaher Corp. | 0.24 | 0.25 | 0.25 | 0.25 | 0.26 | 0.30 | 0.28 | 0.28 | 0.28 | 0.29 | 0.30 | 0.32 | 0.33 | 0.35 | 0.32 | 0.33 | 0.35 | 0.37 | 0.38 | 0.46 | ||||||
| Eli Lilly & Co. | 0.70 | 0.69 | 0.68 | 0.67 | 0.70 | 0.64 | 0.63 | 0.63 | 0.60 | 0.61 | 0.66 | 0.64 | 0.65 | 0.69 | 0.72 | 0.70 | 0.75 | 0.78 | 0.80 | 0.85 | ||||||
| Gilead Sciences Inc. | 0.58 | 0.56 | 0.56 | 0.59 | 0.52 | 0.53 | 0.54 | 0.55 | 0.54 | 0.54 | 0.56 | 0.57 | 0.56 | 0.56 | 0.60 | 0.61 | 0.63 | 0.63 | 0.57 | 0.52 | ||||||
| Johnson & Johnson | 0.34 | 0.34 | 0.37 | 0.32 | 0.30 | 0.30 | 0.38 | 0.43 | 0.34 | 0.30 | 0.30 | 0.31 | 0.31 | 0.33 | 0.32 | 0.34 | 0.36 | 0.37 | 0.33 | 0.31 | ||||||
| Merck & Co. Inc. | 0.44 | 0.46 | 0.46 | 0.46 | 0.48 | 0.46 | 0.49 | 0.40 | 0.40 | 0.41 | 0.42 | 0.44 | 0.46 | 0.42 | 0.44 | 0.54 | 0.56 | 0.50 | 0.53 | 0.52 | ||||||
| Pfizer Inc. | 0.42 | 0.42 | 0.44 | 0.43 | 0.45 | 0.40 | 0.40 | 0.26 | 0.27 | 0.28 | 0.32 | 0.31 | 0.33 | 0.35 | 0.36 | 0.37 | 0.39 | 0.49 | 0.50 | 0.45 | ||||||
| Thermo Fisher Scientific Inc. | 0.39 | 0.42 | 0.43 | 0.44 | 0.43 | 0.44 | 0.44 | 0.45 | 0.44 | 0.40 | 0.42 | 0.45 | 0.46 | 0.36 | 0.34 | 0.35 | 0.39 | 0.40 | 0.42 | 0.41 | ||||||
| Vertex Pharmaceuticals Inc. | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.06 | 0.08 | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= 2,704,400 ÷ 32,058,000 = 0.08
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Regeneron Pharmaceuticals Inc. debt to capital ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
Debt to Assets
Regeneron Pharmaceuticals Inc., debt to assets calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Debt | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 1,500,000) | —) | ||||||
| Finance lease liabilities, current portion | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | 719,700) | 719,000) | 718,400) | 717,800) | —) | —) | —) | —) | ||||||
| Long-term debt | 1,984,400) | 1,984,000) | 1,983,600) | 1,983,300) | 1,982,900) | 1,982,600) | 1,982,200) | 1,981,800) | 1,981,400) | 1,981,100) | 1,980,700) | 1,980,400) | 1,980,000) | 1,979,600) | 1,979,200) | 1,978,900) | 1,978,500) | 1,978,300) | —) | —) | ||||||
| Finance lease liabilities, excluding current portion | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | 720,000) | —) | —) | —) | —) | 717,200) | 716,500) | 715,900) | 715,200) | ||||||
| Total debt | 2,704,400) | 2,704,000) | 2,703,600) | 2,703,300) | 2,702,900) | 2,702,600) | 2,702,200) | 2,701,800) | 2,701,400) | 2,701,100) | 2,700,700) | 2,700,400) | 2,699,700) | 2,698,600) | 2,697,600) | 2,696,700) | 2,695,700) | 2,694,800) | 2,215,900) | 715,200) | ||||||
| Total assets | 37,759,400) | 37,441,900) | 36,086,800) | 34,369,600) | 33,080,200) | 32,163,300) | 30,657,500) | 30,059,900) | 29,214,500) | 27,677,800) | 27,205,800) | 26,348,700) | 25,434,800) | 23,671,500) | 21,485,900) | 17,772,200) | 17,163,300) | 16,084,000) | 14,428,700) | 15,757,500) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to assets1 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.13 | 0.15 | 0.16 | 0.17 | 0.15 | 0.05 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 0.50 | 0.50 | 0.50 | 0.50 | 0.44 | 0.45 | 0.45 | 0.46 | 0.46 | 0.49 | 0.51 | 0.51 | 0.52 | 0.54 | 0.56 | 0.57 | 0.57 | 0.58 | 0.58 | 0.74 | ||||||
| Amgen Inc. | 0.65 | 0.66 | 0.69 | 0.69 | 0.67 | 0.67 | 0.68 | 0.69 | 0.60 | 0.61 | 0.62 | 0.62 | 0.54 | 0.58 | 0.55 | 0.52 | 0.52 | 0.53 | 0.53 | 0.52 | ||||||
| Bristol-Myers Squibb Co. | 0.54 | 0.53 | 0.55 | 0.56 | 0.42 | 0.41 | 0.40 | 0.40 | 0.41 | 0.40 | 0.42 | 0.44 | 0.41 | 0.40 | 0.41 | 0.41 | 0.43 | 0.36 | 0.36 | 0.36 | ||||||
| Danaher Corp. | 0.21 | 0.22 | 0.22 | 0.22 | 0.22 | 0.25 | 0.23 | 0.23 | 0.23 | 0.24 | 0.25 | 0.26 | 0.27 | 0.29 | 0.26 | 0.27 | 0.28 | 0.30 | 0.31 | 0.38 | ||||||
| Eli Lilly & Co. | 0.43 | 0.41 | 0.40 | 0.41 | 0.39 | 0.35 | 0.34 | 0.36 | 0.33 | 0.33 | 0.36 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.36 | 0.39 | 0.39 | 0.42 | ||||||
| Gilead Sciences Inc. | 0.45 | 0.43 | 0.44 | 0.45 | 0.40 | 0.40 | 0.40 | 0.41 | 0.40 | 0.40 | 0.42 | 0.42 | 0.39 | 0.41 | 0.44 | 0.45 | 0.46 | 0.48 | 0.43 | 0.40 | ||||||
| Johnson & Johnson | 0.20 | 0.20 | 0.23 | 0.20 | 0.18 | 0.18 | 0.24 | 0.27 | 0.21 | 0.18 | 0.18 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.20 | 0.22 | 0.19 | 0.18 | ||||||
| Merck & Co. Inc. | 0.32 | 0.32 | 0.34 | 0.32 | 0.33 | 0.33 | 0.35 | 0.29 | 0.28 | 0.28 | 0.30 | 0.30 | 0.31 | 0.28 | 0.29 | 0.34 | 0.35 | 0.32 | 0.34 | 0.33 | ||||||
| Pfizer Inc. | 0.30 | 0.31 | 0.32 | 0.31 | 0.32 | 0.30 | 0.30 | 0.18 | 0.18 | 0.19 | 0.21 | 0.20 | 0.21 | 0.22 | 0.23 | 0.25 | 0.26 | 0.35 | 0.36 | 0.31 | ||||||
| Thermo Fisher Scientific Inc. | 0.32 | 0.35 | 0.36 | 0.37 | 0.35 | 0.36 | 0.36 | 0.37 | 0.35 | 0.32 | 0.33 | 0.36 | 0.37 | 0.29 | 0.28 | 0.28 | 0.31 | 0.33 | 0.35 | 0.34 | ||||||
| Vertex Pharmaceuticals Inc. | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Debt to assets = Total debt ÷ Total assets
= 2,704,400 ÷ 37,759,400 = 0.07
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Regeneron Pharmaceuticals Inc. debt to assets ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |
Financial Leverage
Regeneron Pharmaceuticals Inc., financial leverage calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Total assets | 37,759,400) | 37,441,900) | 36,086,800) | 34,369,600) | 33,080,200) | 32,163,300) | 30,657,500) | 30,059,900) | 29,214,500) | 27,677,800) | 27,205,800) | 26,348,700) | 25,434,800) | 23,671,500) | 21,485,900) | 17,772,200) | 17,163,300) | 16,084,000) | 14,428,700) | 15,757,500) | ||||||
| Stockholders’ equity | 29,353,600) | 29,325,900) | 28,205,800) | 26,991,100) | 25,973,100) | 24,904,400) | 24,017,900) | 23,495,200) | 22,664,000) | 21,438,800) | 20,687,800) | 19,914,700) | 18,768,800) | 17,258,000) | 15,127,300) | 11,977,000) | 11,025,300) | 10,125,500) | 9,057,400) | 12,133,000) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Financial leverage1 | 1.29 | 1.28 | 1.28 | 1.27 | 1.27 | 1.29 | 1.28 | 1.28 | 1.29 | 1.29 | 1.32 | 1.32 | 1.36 | 1.37 | 1.42 | 1.48 | 1.56 | 1.59 | 1.59 | 1.30 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 40.65 | 23.78 | 20.94 | 18.59 | 13.00 | 11.26 | 10.52 | 10.14 | 8.04 | 8.84 | 9.77 | 8.80 | 9.51 | 10.99 | 11.77 | 10.98 | 11.51 | 9.80 | 10.17 | — | ||||||
| Amgen Inc. | 15.63 | 12.07 | 15.34 | 18.51 | 15.59 | 11.83 | 13.31 | 16.59 | 17.79 | 17.44 | 24.51 | 64.62 | 9.13 | 7.91 | 7.25 | 6.70 | 6.69 | 5.90 | 6.10 | 6.50 | ||||||
| Bristol-Myers Squibb Co. | 5.67 | 5.46 | 5.56 | 6.01 | 3.23 | 3.15 | 2.92 | 2.96 | 3.12 | 3.01 | 3.08 | 3.26 | 3.04 | 2.98 | 3.01 | 2.99 | 3.13 | 2.50 | 2.61 | 2.59 | ||||||
| Danaher Corp. | 1.57 | 1.57 | 1.57 | 1.56 | 1.58 | 1.67 | 1.64 | 1.65 | 1.68 | 1.72 | 1.76 | 1.80 | 1.84 | 1.90 | 1.82 | 1.87 | 1.92 | 1.92 | 1.97 | 2.22 | ||||||
| Eli Lilly & Co. | 5.55 | 5.31 | 5.30 | 4.99 | 5.94 | 5.16 | 4.95 | 4.75 | 4.65 | 4.71 | 5.51 | 5.03 | 5.44 | 6.21 | 7.42 | 6.79 | 8.27 | 9.10 | 10.25 | 13.35 | ||||||
| Gilead Sciences Inc. | 3.05 | 2.95 | 2.93 | 3.21 | 2.72 | 2.80 | 2.95 | 2.95 | 2.97 | 2.97 | 3.11 | 3.17 | 3.23 | 3.13 | 3.45 | 3.56 | 3.76 | 3.49 | 3.10 | 2.71 | ||||||
| Johnson & Johnson | 2.52 | 2.54 | 2.53 | 2.46 | 2.44 | 2.33 | 2.55 | 2.77 | 2.44 | 2.35 | 2.33 | 2.39 | 2.46 | 2.55 | 2.54 | 2.62 | 2.76 | 2.65 | 2.51 | 2.53 | ||||||
| Merck & Co. Inc. | 2.53 | 2.64 | 2.58 | 2.62 | 2.84 | 2.59 | 2.70 | 2.30 | 2.37 | 2.41 | 2.48 | 2.61 | 2.77 | 2.61 | 2.72 | 3.37 | 3.62 | 3.08 | 3.28 | 3.24 | ||||||
| Pfizer Inc. | 2.42 | 2.38 | 2.47 | 2.40 | 2.54 | 2.22 | 2.22 | 1.94 | 2.06 | 2.10 | 2.24 | 2.23 | 2.35 | 2.37 | 2.43 | 2.31 | 2.44 | 2.74 | 2.77 | 2.56 | ||||||
| Thermo Fisher Scientific Inc. | 1.96 | 2.05 | 2.08 | 2.13 | 2.11 | 2.14 | 2.15 | 2.24 | 2.21 | 2.08 | 2.14 | 2.26 | 2.33 | 1.90 | 1.84 | 1.88 | 2.00 | 2.01 | 2.06 | 2.05 | ||||||
| Vertex Pharmaceuticals Inc. | 1.37 | 1.42 | 1.36 | 1.29 | 1.29 | 1.32 | 1.32 | 1.31 | 1.30 | 1.28 | 1.31 | 1.31 | 1.33 | 1.32 | 1.33 | 1.35 | 1.35 | 1.39 | 1.36 | 1.38 | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= 37,759,400 ÷ 29,353,600 = 1.29
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Regeneron Pharmaceuticals Inc. financial leverage ratio decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 exceeding Q2 2024 level. |
Interest Coverage
Regeneron Pharmaceuticals Inc., interest coverage calculation (quarterly data)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net income | 917,700) | 1,340,600) | 1,432,300) | 722,000) | 1,159,600) | 1,007,800) | 968,400) | 817,800) | 1,197,100) | 1,315,700) | 852,100) | 973,500) | 2,229,000) | 1,632,200) | 3,098,900) | 1,115,200) | 1,149,200) | 842,100) | 897,300) | 624,600) | ||||||
| Add: Income tax expense | 40,400) | 152,400) | 195,800) | (21,300) | (12,000) | 103,000) | 114,500) | 40,200) | 127,600) | 194,100) | 111,100) | 87,600) | 274,400) | 184,400) | 653,900) | 137,800) | 75,400) | 156,200) | 21,600) | 44,000) | ||||||
| Add: Interest expense | 10,500) | 13,800) | 14,800) | 16,100) | 18,300) | 17,800) | 18,900) | 18,000) | 17,400) | 15,300) | 13,100) | 13,600) | 14,100) | 14,200) | 14,400) | 14,600) | 14,800) | 26,300) | 9,700) | 6,100) | ||||||
| Earnings before interest and tax (EBIT) | 968,600) | 1,506,800) | 1,642,900) | 716,800) | 1,165,900) | 1,128,600) | 1,101,800) | 876,000) | 1,342,100) | 1,525,100) | 976,300) | 1,074,700) | 2,517,500) | 1,830,800) | 3,767,200) | 1,267,600) | 1,239,400) | 1,024,600) | 928,600) | 674,700) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Interest coverage1 | 87.59 | 79.88 | 69.47 | 57.85 | 58.52 | 61.70 | 69.61 | 73.97 | 82.80 | 108.62 | 116.35 | 163.24 | 163.75 | 139.74 | 104.12 | 68.20 | 67.97 | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Interest Coverage, Competitors2 | ||||||||||||||||||||||||||
| Amgen Inc. | 2.46 | 2.45 | 2.10 | 2.38 | 3.73 | 4.54 | 5.43 | 6.51 | 6.22 | 6.83 | 6.97 | 6.40 | 6.60 | 6.46 | 6.48 | 7.64 | 7.44 | — | — | — | ||||||
| Danaher Corp. | 17.71 | 16.11 | 17.61 | 17.81 | 18.64 | 23.66 | 29.65 | 35.60 | 40.30 | 41.32 | 35.26 | 33.54 | 32.92 | 28.74 | 25.87 | 21.54 | 17.35 | — | — | — | ||||||
| Gilead Sciences Inc. | 1.71 | 1.18 | 2.58 | 2.11 | 8.27 | 8.88 | 9.03 | 8.84 | 7.22 | 5.80 | 6.73 | 6.97 | 9.27 | 10.06 | 7.61 | 2.93 | 2.70 | — | — | — | ||||||
| Johnson & Johnson | 23.10 | 23.92 | 26.40 | 29.06 | 20.51 | 19.09 | 23.89 | 31.49 | 79.71 | 141.63 | 160.27 | 164.15 | 125.46 | 94.27 | 87.06 | 73.87 | 83.07 | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | 6.03 | 5.62 | 5.62 | 5.53 | 5.54 | 5.98 | 6.64 | 8.28 | 11.56 | 13.59 | 15.70 | 16.73 | 17.49 | 19.94 | 19.52 | 17.58 | 14.07 | — | — | — | ||||||
| Vertex Pharmaceuticals Inc. | 9.12 | 7.76 | 6.14 | 111.61 | 100.32 | 96.54 | 90.90 | 82.27 | 78.23 | 70.08 | 66.72 | 48.17 | 45.40 | 44.83 | 40.33 | 55.95 | 54.60 | — | — | — | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Interest coverage
= (EBITQ4 2024
+ EBITQ3 2024
+ EBITQ2 2024
+ EBITQ1 2024)
÷ (Interest expenseQ4 2024
+ Interest expenseQ3 2024
+ Interest expenseQ2 2024
+ Interest expenseQ1 2024)
= (968,600 + 1,506,800 + 1,642,900 + 716,800)
÷ (10,500 + 13,800 + 14,800 + 16,100)
= 87.59
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Regeneron Pharmaceuticals Inc. interest coverage ratio improved from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024. |